Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

Autoimmune hair loss may be linked to increased Th1 and Th17 cells and decreased Th2 cells.

Fat-derived stem cells show promise for treating skin issues and improving wound healing, but more research is needed to confirm the best way to use them.

The photolyase-based device significantly changed the size and heat of potential skin cancer areas in patients.

Higher levels of IL-17A and IL-2 are linked to alopecia areata.

Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.

Combined therapy reduces inflammation and restores immune balance in alopecia areata patients.

A specific ATR gene mutation is linked to a hereditary oropharyngeal cancer syndrome.

Hair follicle stem cells reduced hair loss and inflammation in mice with a condition similar to human alopecia.

Alopecia Areata might be linked to Crohn's disease.

New cytokine-targeted therapies show promise for treating alopecia areata.

Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.

Early intervention is important for limited systemic sclerosis patients due to higher pain and ulceration risks.

Different types of atopic dermatitis were linked to specific genetic and immune changes, suggesting that severe cases might need stronger immune-targeting treatments.

Targeting specific biomarkers and immune signals is more effective and safer for treating inflammatory skin diseases.

Adipose-derived stem cells can help repair tissue in lipodystrophy patients.

Deleting the MAD2L1 gene in mice led to rapid tumor growth despite chromosomal instability.

Controlled delivery of specific RNA and IL-4 restored hair growth in mice with autoimmune alopecia.

Alefacept does not effectively treat severe alopecia areata.

JAK inhibitors are effective for treating moderate-to-severe alopecia areata.

Alopecia areata is caused by the immune system attacking hair follicles.

SOCS1 and SOCS3 help control skin inflammation and are important for developing treatments for skin diseases.

The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.

Stem cells help control the immune response to improve wound healing.

Ifidancitinib, a JAK inhibitor, effectively regrows hair in mice with alopecia by tiring out harmful T cells.

Alopecia areata can be triggered by specific immune cells without genetic or environmental factors.

Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.

KRTAP2-3 could help predict cancer recurrence by identifying specific cancer cells.

Using a collagen sponge scaffold helps stem cells become more like skin cells.

Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.